IT1400309B1 - Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso. - Google Patents

Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.

Info

Publication number
IT1400309B1
IT1400309B1 ITRM2010A000230A ITRM20100230A IT1400309B1 IT 1400309 B1 IT1400309 B1 IT 1400309B1 IT RM2010A000230 A ITRM2010A000230 A IT RM2010A000230A IT RM20100230 A ITRM20100230 A IT RM20100230A IT 1400309 B1 IT1400309 B1 IT 1400309B1
Authority
IT
Italy
Prior art keywords
xanthin
association
calcium antagonists
oxidase
inhibitors
Prior art date
Application number
ITRM2010A000230A
Other languages
English (en)
Inventor
Francesco Melani
Sandro Giuliani
Carlo Alberto Maggi
Original Assignee
Menarini Int Operations Lu Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Menarini Int Operations Lu Sa filed Critical Menarini Int Operations Lu Sa
Priority to ITRM2010A000230A priority Critical patent/IT1400309B1/it
Priority to PCT/EP2011/057326 priority patent/WO2011141381A1/en
Priority to TW100116122A priority patent/TW201206433A/zh
Publication of ITRM20100230A1 publication Critical patent/ITRM20100230A1/it
Application granted granted Critical
Publication of IT1400309B1 publication Critical patent/IT1400309B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ITRM2010A000230A 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso. IT1400309B1 (it)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ITRM2010A000230A IT1400309B1 (it) 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
PCT/EP2011/057326 WO2011141381A1 (en) 2010-05-10 2011-05-06 Association of xanthine oxidase inhibitors and calcium antagonists and use thereof
TW100116122A TW201206433A (en) 2010-05-10 2011-05-09 Association of xanthine oxidase inhibitors and calcium antagonists and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM2010A000230A IT1400309B1 (it) 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.

Publications (2)

Publication Number Publication Date
ITRM20100230A1 ITRM20100230A1 (it) 2011-11-11
IT1400309B1 true IT1400309B1 (it) 2013-05-24

Family

ID=42753374

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM2010A000230A IT1400309B1 (it) 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.

Country Status (3)

Country Link
IT (1) IT1400309B1 (it)
TW (1) TW201206433A (it)
WO (1) WO2011141381A1 (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016155815A1 (en) * 2015-04-01 2016-10-06 Ceva Sante Animale Oral solid dosage form of amlodipine and veterinary uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) * 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
CA2073981C (en) 1990-11-30 2002-01-08 Shiro Kondo 2-arylthiazole derivatives and pharmaceutical composition thereof
GT199800127A (es) 1997-08-29 2000-02-01 Combinaciones terapeuticas.
PL200710B1 (pl) 1998-06-19 2009-01-30 Teijin Pharma Ltd Polimorfy kwasu 2-(3-cyjano-4-izobutyloksyfenylo)-4-metylo-5-tiazolokarboksylowego i sposób ich wytwarzania
SG142116A1 (en) 1998-07-10 2008-05-28 Novartis Ag Antihypersensitive combination of valsartan and calcium channel blocker
US20040122067A1 (en) 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
CA2617248C (en) * 2005-08-03 2015-09-29 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
WO2007062028A2 (en) 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Treatment of qt interval prolongation and diseases associated therewith
WO2008064015A1 (en) 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America Methods for preserving renal function using xanthine oxidoreductase inhibitors

Also Published As

Publication number Publication date
ITRM20100230A1 (it) 2011-11-11
WO2011141381A1 (en) 2011-11-17
TW201206433A (en) 2012-02-16

Similar Documents

Publication Publication Date Title
CY2020025I1 (el) Αναστολεις βητα-λακταμασων
SMT201600135B (it) Nuovi inibitori della s-nitrosoglutatione riduttasi
SMT201600278B (it) Inibitori della benzossazolo chinasi e metodi d'uso
LTPA2019506I1 (lt) Nenukleozidinės reversinės transkriptazės inhibitoriai
SMT201600021B (it) Nuovi composti di chinolina sostituiti come inibitori della s-nitrosoglutatione reduttasi
SMT201600023B (it) Composti piridazinonici e loro uso come inibitori di daao
DK2536722T3 (da) Bicycliske forbindelser og deres anvendelse som dual-c-src-/jak-inhibitorer
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
BRPI0915231A2 (pt) compostos inibidores de quinase e métodos de uso
BRPI1012333A2 (pt) atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
ECSP12012034A (es) Antagonistas de pcsk9
CO6781493A2 (es) Inhibidores de la faah
BR112013025353A2 (pt) combinações de compostos de inibidores de akt e erlotinibe e métodos de uso
DK3590934T3 (da) Pyrazolylquinoxalinkinasehæmmere
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
EP2480576A4 (en) ANTAGONISTS OF PCSK9
DOP2011000397A (es) Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a
BR112013006016A2 (pt) compostos de azabenzotiazol, composições e métodos de uso
SMT201700064B (it) Antagonisti di d2, metodi di sintesi e metodi di uso
TN2012000485A1 (en) Predictive markers useful in the treatment of fragile x syndrome (fxs)
BRPI0911332A2 (pt) composições e uso de inibidores de epas1
BRPI1014544A2 (pt) anticorpors anti-il-17f e metodos de uso dos mesmos
DK2513105T3 (da) 2-arylimidazolderivater som pde10a-enzyminhibitorer
BRPI0922344A2 (pt) inibidores de tfpi e métodos de uso
BR112013010331A2 (pt) composições adesivas crepadas e métodos de uso dessas composições